Case 7-2014: A 27-year-old man with diarrhea, fatigue, and eosinophilia

New England Journal of Medicine

Volumn 370, Issue 9, 2014, Pages 861-872

  Fathi, Amir T ^a,b   Dec Jr , G William ^a,b   Richter, James M ^a,b   Chen, Yi Bin ^a,b   Schwartzenberg, Shmuel S ^a,b   Holmvang, Godtfred ^a,b   Hasserjian, Robert P ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; HEPATITIS A ANTIBODY; MESALAZINE; PARACETAMOL; ANTINEOPLASTIC ANTIMETABOLITE; CYTARABINE;

ABDOMINAL CRAMP; ADULT; ARTICLE; BLOATING; BLOOD CELL COUNT; CASE REPORT; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DIFFERENTIAL DIAGNOSIS; EOSINOPHILIA; ERYTHEMA; EXERCISE TOLERANCE; FATIGUE; FECES ANALYSIS; FEMALE; HEADACHE; HUMAN; HYPEREOSINOPHILIC SYNDROME; IDIOPATHIC HYPEREOSINOPHILIC SYNDROME; INTESTINE BIOPSY; LABORATORY DIAGNOSIS; LEUKOCYTOSIS; LYMPH NODE BIOPSY; MESENTERIC VEIN THROMBOSIS; NAUSEA; PAPULAR RASH; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SPLENOMEGALY; TENESMUS; ULCERATIVE COLITIS; WEIGHT REDUCTION; BIOPSY; BONE MARROW; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; ECHOGRAPHY; HEART DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MALE; PATHOLOGY; RECTUM; STOMACH;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; BIOPSY; BONE MARROW; COLITIS, ULCERATIVE; CYTARABINE; DIAGNOSIS, DIFFERENTIAL; DIARRHEA; EOSINOPHILIA; FATIGUE; HEART DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYPEREOSINOPHILIC SYNDROME; MALE; RECTUM; SPLENOMEGALY; STOMACH;

EID: 84896703004     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcpc1302331     Document Type: Article

References (60)

1. Farahi N, Singh NR, Heard S, et al. Use of 111-Indium-labeled autologous eosinophils to establish the in vivo kinetics of human eosinophils in healthy subjects. Blood 2012;120:4068-71.
2. Valent P, Gleich GJ, Reiter A, et al. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol 2012;5:157-76.
3. Gill GV, Bailey JW. Eosinophilia as a marker for chronic strongyloidiasis - use of a serum ELISA test to detect asymptomatic cases. Ann Trop Med Parasitol 1989;83:249-52. (Pubitemid 19183517)
4. Meltzer E, Percik R, Shatzkes J, Sidi Y, Schwartz E. Eosinophilia among returning travelers: a practical approach. Am J Trop Med Hyg 2008;78:702-9. (Pubitemid 351845123)
5. Weller PF. Eosinophilia in travelers. Med Clin North Am 1992;76:1413-32.
6. Nutman TB, Ottesen EA, Ieng S, et al. Eosinophilia in Southeast Asian refugees: evaluation at a referral center. J Infect Dis 1987;155:309-13. (Pubitemid 17022874)
7. Libman MD, MacLean JD, Gyorkos TW. Screening for schistosomiasis, filariasis, and strongyloidiasis among expatriates returning from the tropics. Clin Infect Dis 1993;17:353-9. (Pubitemid 23261447)
8. Kaplan MH, Hall WW, Susin M, et al. Syndrome of severe skin disease, eosinophilia, and dermatopathic lymphadenopathy in patients with HTLV-II complicating human immunodeficiency virus infection. Am J Med 1991;91:300-9.
9. Skiest DJ, Keiser P. Clinical significance of eosinophilia in HIV-infected individuals. Am J Med 1997;102:449-53. (Pubitemid 27268482)
10. Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990;323:1033-9. (Pubitemid 20336962)
11. Noh G, Jin H, Lee J, Noh J, Lee WM, Lee S. Eosinophilia as a predictor of food allergy in atopic dermatitis. Allergy Asthma Proc 2010;31:e18-24.
12. Ganeva M, Gancheva T, Lazarova R, et al. Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review. Int J Dermatol 2008;47:853-60.
13. Morice AH, Kumwenda J, Qureshi N, Curran A. Mesalazine activation of eosinophil. Lancet 1997;350:1105.
14. Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med 2011;124:588-97.
15. Grau RG. Churg-Strauss syndrome: 2005-2008 update. Curr Rheumatol Rep 2008;10:453-8.
16. Atanes A, Fernández V, Núñez R, et al. Idiopathic eosinophilic synovitis: case report and review of the literature. Scand J Rheumatol 1996;25:183-5. (Pubitemid 26180282)
17. Beishuizen A, Vermes I, Hylkema BS, Haanen C. Relative eosinophilia and functional adrenal insufficiency in critically ill patients. Lancet 1999;353:1675-6. (Pubitemid 29224529)
18. Renston JP, Goldman ES, Hsu RM, Tomashefski JF Jr. Peripheral blood eosinophilia in association with sarcoidosis. Mayo Clin Proc 2000;75:586-90. (Pubitemid 30395920)
19. Terrier B, Fontaine H, Schmitz J, et al. Coexistence and parallel evolution of hypereosinophilic syndrome, autoimmune hepatitis, and ulcerative colitis suggest common pathogenic features. Am J Gastroenterol 2007;102:1132-4. (Pubitemid 46698254)
20. Benfield GF, Asquith P. Blood eosinophilia and ulcerative colitis - influence of ethnic origin. Postgrad Med J 1986;62:1101-5. (Pubitemid 17204460)
21. Balian A, Bonte E, Naveau S, et al. Intratumoral production of interleukin-5 leading to paraneoplastic peripheral eosinophilia in hepatocellular carcinoma. J Hepatol 2001;34:355-6. (Pubitemid 32176466)
22. Grimaldi JC, Meeker TC. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. Blood 1989;73:2081-5. (Pubitemid 19179537)
23. Lammel V, Stoeckle C, Padberg B, et al. Hypereosinophilia driven by GM-CSF in large-cell carcinoma of the lung. Lung Cancer 2012;76:493-5.
24. Navarro-Román L, Medeiros LJ, Kingma DW, et al. Malignant lymphomas of B-cell lineage with marked tissue eosinophilia: a report of five cases. Am J Surg Pathol 1994;18:347-56. (Pubitemid 24093599)
25. Samoszuk M, Nansen L. Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. Blood 1990;75:13-6. (Pubitemid 20031482)
26. Gotlib J. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management. Am J Hematol 2011;86:677-88.
27. Helbig G, Wieczorkiewicz A, Dziaczkowska-Suszek J, Majewski M, Kyrcz-Krzemien S. T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome. Haematologica 2009;94:1236-41.
28. Sadrzadeh H, Abdel-Wahab O, Fathi AT. Molecular alterations underlying eosinophilic and mast cell malignancies. Discov Med 2011;12:481-93.
29. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003;102:3093-6. (Pubitemid 37314742)
30. Pardanani A, Reeder T, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003;101:3391-7. (Pubitemid 36857919)
31. Fukushima K, Matsumura I, Ezoe S, et al. FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells. J Biol Chem 2009;284:7719-32.
32. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003;101:4660-6. (Pubitemid 36857718)
33. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002;347:481-7. (Pubitemid 34879335)
34. David M, Cross NC, Burgstaller S, et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007;109:61-4. (Pubitemid 46053044)
35. Erben P, Gosenca D, Müller MC, et al. Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica 2010;95:738-44.
36. Verstovsek S, Giles FJ, Quintás-Cardama A, et al. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leuk Res 2006;30:1499-505. (Pubitemid 44573482)
37. Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 2002;107:101-7. (Pubitemid 34264174)
38. Popovici C, Zhang B, Grégoire MJ, et al. The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood 1999;93:1381-9. (Pubitemid 29076154)
39. Tefferi A, Gotlib J, Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc 2010;85:158-64.
40. Xiao S, Nalabolu SR, Aster JC, et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet 1998;18:84-7. (Pubitemid 28027887)
41. Gotlib J. Eosinophilic myeloid disorders: new classification and novel therapeutic strategies. Curr Opin Hematol 2010;17:117-24.
42. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975;54:1-27.
43. Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH. NIH conference - the idiopathic hypereosinophilic syndrome: clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982;97:78-92. (Pubitemid 12091287)
44. Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009;124(6):1319.e3-1325.e3.
45. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994;83:2759-79. (Pubitemid 24142705)
46. Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med 1978;89:167-72. (Pubitemid 8395466)
47. Chusid MJ, Dale DC. Eosinophilic leukemia: remission with vincristine and hydroxyurea. Am J Med 1975;59:297-300.
48. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-14. (Pubitemid 36359296)
49. Butterfield JH. Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalphanegative hypereosinophilic syndrome. Leuk Res 2009;33:1127-9.
50. Baumgartner C, Gleixner KV, Peter B, et al. Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. Exp Hematol 2008;36:1244-53.
51. Butterfield JH, Gleich GJ. Response of six patients with idiopathic hypereosinophilic syndrome to interferon alfa. J Allergy Clin Immunol 1994;94:1318-26.
52. Butterfield JH. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol 2005;114:26-40. (Pubitemid 40911570)
53. Verstovsek S, Tefferi A, Kantarjian H, et al. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res 2009;15:368-73.
54. Plötz SG, Simon HU, Darsow U, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003;349:2334-9. (Pubitemid 37521232)
55. Ginsberg F, Parrillo JE. Eosinophilic myocarditis. Heart Fail Clin 2005;1:419-29.
56. Chun W, Grist TM, Kamp TJ, Warner TF, Christian TF. Images in cardiovascular medicine: infiltrative eosinophilic myocarditis diagnosed and localized by cardiac magnetic resonance imaging. Circulation 2004;110(3):e19.
57. Archimbaud E, Guyotat D, Guillaume C, Godard J, Fiere D. Hypereosinophilic syndrome with multiple organ dysfunction treated by allogeneic bone marrow transplantation. Am J Hematol 1988;27:302-3.
58. Sigmund DA, Flessa HC. Hypereosinophilic syndrome: successful allogeneic bone marrow transplantation. Bone Marrow Transplant 1995;15:647-8.
59. Esteva-Lorenzo FJ, Meehan KR, Spitzer TR, Mazumder A. Allogeneic bone marrow transplantation in a patient with hypereosinophilic syndrome. Am J Hematol 1996;51:164-5. (Pubitemid 26060007)
60. Ueno NT, Anagnostopoulos A, Rondón G, et al. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 2002;119:131-4. (Pubitemid 35176512)